Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YIV-906 and Sorafenib in HBV(+) Advanced HCC
NCT04000737Phase 2Completed
- Sponsor
- Yiviva
- Start
- Jan 2020
- Primary completion
- Mar 2024
- Modality
- Botanical Extract
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib + YIV-906 with Sorafenib + Placebo (2 arms). Primary endpoint: Progression Free Survival up to 24 months. Started Jan 2020; status: completed.
02
Drugs
PHY906
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04000737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000737.